Pdl Biopharma Inc (PDLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2019 | 03-2019 | 12-2018 | 09-2018 | 06-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 284,941 | 366,324 | 394,590 | 400,984 | 395,653 |
| Receivables | 17,872 | 15,739 | 21,648 | 15,437 | 19,531 |
| Inventories | 16,263 | 15,547 | 18,942 | 12,515 | 14,801 |
| Other current assets | 63,280 | 63,056 | 63,042 | 60,280 | 58,058 |
| TOTAL | $399,703 | $477,546 | $517,217 | $507,749 | $508,671 |
| Non-Current Assets | |||||
| PPE Net | 6,914 | 7,110 | 7,387 | 8,838 | 9,223 |
| Investments And Advances | 88,533 | 0 | 0 | 0 | 0 |
| Intangibles | 366,091 | 425,893 | 427,829 | 431,186 | 389,635 |
| Other Non-Current Assets | 29,220 | 12,984 | 11,303 | 36,654 | 38,466 |
| TOTAL | $490,758 | $445,987 | $446,519 | $476,678 | $437,324 |
| Total Assets | $890,461 | $923,533 | $963,736 | $984,427 | $945,995 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 14,812 | 12,430 | 13,142 | 9,011 | 11,212 |
| Accrued Expenses | N/A | 30,867 | N/A | N/A | N/A |
| TOTAL | $38,336 | $43,318 | $52,470 | $46,672 | $45,723 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | 126,567 | N/A | N/A | N/A |
| Other Non-Current Liabilities | 186,796 | 59,927 | 181,487 | 198,368 | 187,644 |
| TOTAL | $186,701 | $186,431 | $181,487 | $198,368 | $187,644 |
| Total Liabilities | $225,037 | $229,749 | $233,957 | $245,040 | $233,367 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 114,203 | 120,655 | 128,109 | 145,976 | 145,400 |
| Common Shares | 1,157 | 1,238 | 1,365 | 1,460 | 1,460 |
| Retained earnings | 759,080 | 790,396 | 828,547 | 835,567 | 811,397 |
| Other shareholders' equity | 652 | 19 | -103 | 0 | 0 |
| TOTAL | $665,424 | $693,784 | $729,779 | $739,387 | $712,628 |
| Total Liabilities And Equity | $890,461 | $923,533 | $963,736 | $984,427 | $945,995 |